| Literature DB >> 28155675 |
Abstract
BACKGROUND: MicroRNAs (miRNAs) are involved in many biological processes by regulating post-transcriptional gene expression. The alterations of the regulatory pathways can cause different diseases including cancer. Although many works have been done to study the gene-miRNA regulatory network, the intertwined relationship is far from being fully understood. The objective of this study is to integrate both gene expression data and miRNA data so as to explore the complex relationships among them.Entities:
Keywords: Data integration; Gene-miRNA network; Module identification
Mesh:
Substances:
Year: 2016 PMID: 28155675 PMCID: PMC5259869 DOI: 10.1186/s12918-016-0357-1
Source DB: PubMed Journal: BMC Syst Biol ISSN: 1752-0509
Fig. 1AUCs for different cutoffs when building the gene-miRNA coexpression network
MiRNA module enrichment results
| No. |
| MiRNAs | Loci |
|---|---|---|---|
| 38 | 2.01E-18 | miR-411, miR-299, miR-758, miR-329-1, miR-543, miR-495, | Chr14 101022066- |
| miR-654, miR-376b, miR-376a-1, miR-381, miR-487b, miR-539, | 101066801 | ||
| miR-487a, miR-382, miR-154, miR-377, miR-409, miR-369, | |||
| miR-376c,miR-889,miR-410 | |||
| 45 | 1.41E-14 | miR-379, miR-411, miR-299, miR-758, miR-329-1, miR-543, | Chr14 101022066- |
| miR-376c, miR-654, miR-376b, miR-376a-1, miR-381, | -101066801 | ||
| miR-487a, miR-382, miR-154, miR-377, miR-409, miR-369, | |||
| miR-495, miR-487b, miR-539, miR-410 | |||
| 5 | 1.29E-15 | miR-411, miR-758, miR-329-1, miR-543, miR-495, | Chr14 101022066- |
| miR-376b, miR-376a-1, miR-487b„ miR-539, miR-889, | -101066801 | ||
| miR-382 miR-154, miR-409, miR-369, | |||
| miR-654,miR-487a, miR-410 | |||
| 2 | 2.19E-02 | miR-379, miR-299, miR-376c, miR-376a-1, miR-381, miR-377 | Chr14 101022066- |
| -101062118 | |||
| 10 | 1.40E-03 | miR-379, miR-299, miR-376c, miR-376a-1, miR-381, miR-377 | Chr14 101022066- |
| -101062118 | |||
| 38 | 2.70E-05 | miR-493, miR-337, miR-433, miR-127, miR-432, miR-136 | Chr14 100869060- |
| -100884783 | |||
| 12 | 1.40E-03 | miR-379, miR-299, miR-376c, miR-376a-1, miR-381, miR-377 | Chr14 101022066- |
| -101062118 | |||
| 21 | 1.26E-02 | miR-379, miR-299, miR-376c, miR-376a-1, miR-381, miR-377 | Chr14 101022066- |
| -101062118 | |||
| 35 | 1.17E-06 | miR-17, miR-18a, miR-19a, miR-20a, miR-19b-1 | Chr13 91350605- |
| -91351391 | |||
| 45 | 5.66E-03 | miR-493, miR-337, miR-433, miR-127, miR-136 | Chr14 100869000- |
| -100885000 | |||
| 18 | 2.13E-04 | miR-424, miR-503, miR-542, miR-450a-1 | ChrX 134546614- |
| -134540262 | |||
| 1 | 4.45E-05 | miR-200b, miR-200a, miR-429 | Chr1 1167104- |
| -1169087 | |||
| 10 | 2.02E-02 | miR-337, miR-127, miR-136 | Chr14 100869060- |
| -100884783 | |||
| 11 | 1.78E-03 | miR-18b, miR-20b, miR-363 | ChrX 134170198- |
| -134169452 | |||
| 22 | 2.83E-03 | miR-508, miR-507, miR-506 | Chr X 147236913- |
| -147230843 | |||
| 35 | 9.44E-04 | miR-106b, miR-93, miR-25 | Chr 7 100093993- |
| -100093643 | |||
| 37 | 9.44E-04 | miR-106b, miR-93, miR-25 | Chr 7 100093993- |
| -100093643 | |||
| 41 | 1.40E-02 | miR-17, miR-19a, miR-20a | Chr 13 91350605- |
| -91351135 |
Enriched KEGG pathways for the gene modules
| No. | Enriched Pathways |
|
|---|---|---|
| 17 | Cytokine-cytokine receptor interaction | 7.40E-05 |
| NOD-like receptor signaling pathway | 1.20E-03 | |
| Chemokine signaling pathway | 5.80E-03 | |
| Hematopoietic cell lineage | 3.30E-02 | |
| Complement and coagulation cascades | 1.80E-01 | |
| Systemic lupus erythematosus | 2.70E-01 | |
| 18 | p53 signaling pathway | 3.50E-03 |
| Small cell lung cancer | 2.70E-03 | |
| Cell cycle | 4.00E-03 | |
| Pathways in cancer | 2.10E-02 | |
| Non-small cell lung cancer | 8.20E-02 | |
| Glioma | 8.00E-02 | |
| Melanoma | 7.70E-02 | |
| Pancreatic cancer | 6.90E-02 | |
| Chronic myeloid leukemia | 6.40E-02 | |
| Prostate cancer | 6.80E-02 | |
| 24 | Cytokine-cytokine receptor interaction | 4.40E-05 |
| NOD-like receptor signaling pathway | 9.40E-04 | |
| Chemokine signaling pathway | 4.30E-03 | |
| Hematopoietic cell lineage | 2.70E-02 | |
| Complement and coagulation cascades | 1.60E-01 | |
| Systemic lupus erythematosus | 2.40E-01 | |
| 28 | Antigen processing and presentation | 4.00E-03 |
| Cytokine-cytokine receptor interaction | 1.20E-02 | |
| Natural killer cell mediated cytotoxicity | 9.20E-02 | |
| Hematopoietic cell lineage | 1.30E-01 | |
| Graft-versus-host disease | 1.70E-01 | |
| Chemokine signaling pathway | 1.40E-01 | |
| NOD-like receptor signaling pathway | 2.70E-01 | |
| Viral myocarditis | 3.00E-01 | |
| 31 | Systemic lupus erythematosus | 1.30E-02 |
| 41 | Small cell lung cancer | 1.30E-03 |
| Chronic myeloid leukemia | 3.10E-02 | |
| Pathways in cancer | 2.40E-02 | |
| Colorectal cancer | 1.90E-02 | |
| Cell cycle | 3.40E-02 | |
| Thyroid cancer | 1.30E-01 | |
| Bladder cancer | 1.60E-01 | |
| Endometrial cancer | 1.80E-01 | |
| Non-small cell lung cancer | 1.60E-01 | |
| Acute myeloid leukemia | 1.60E-01 | |
| Glioma | 1.60E-01 | |
| p53 signaling pathway | 1.50E-01 | |
| Melanoma | 1.50E-01 | |
| Pancreatic cancer | 1.40E-01 | |
| Prostate cancer | 1.60E-01 | |
| 43 | ECM-receptor interaction | 1.20E-09 |
| Focal adhesion | 6.70E-06 | |
| Vascular smooth muscle contraction | 1.60E-01 | |
| 21 | Focal adhesion | 8.80E-01 |
| 22 | ECM-receptor interaction | 8.30E-01 |
| 35 | Acute myeloid leukemia | 8.20E-01 |
| p53 signaling pathway | 6.40E-01 | |
| Chronic myeloid leukemia | 5.20E-01 | |
| 37 | Hypertrophic cardiomyopathy (HCM) | 7.00E-02 |
| Gap junction | 2.70E-01 | |
| Dilated cardiomyopathy | 2.10E-01 | |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | 4.60E-01 | |
| MAPK signaling pathway | 7.80E-01 | |
| 45 | Pathways in cancer | 7.30E-01 |
| Basal cell carcinoma | 5.00E-01 | |
| Hedgehog signaling pathway | 3.70E-01 |
Cancer associated miRNAs in the modules shown in Table 1
| Module No. | 1 | 2 | 5 | 10 | 11 | 12 | 18 |
|---|---|---|---|---|---|---|---|
| Total No. of miRNAs | 5 | 13 | 21 | 9 | 6 | 9 | 12 |
| No. of cancer miRNAs | 5 | 9 | 8 | 6 | 5 | 6 | 10 |
|
| 0 | 1.80E-04 | 4.82E-02 | 3.40E-03 | 1.77E-03 | 3.40E-03 | 4.74E-06 |
| Module No. | 21 | 22 | 35 | 37 | 38 | 41 | 45 |
| Total No. of miRNAs | 11 | 11 | 12 | 12 | 29 | 11 | 39 |
| No. of cancer miRNAs | 7 | 2 | 10 | 12 | 13 | 10 | 15 |
|
| 2.17E-03 | 7.00E-01 | 4.74E-06 | 0 | 2.29E-03 | 9.58E-07 | 6.43E-03 |
Fig. 2Network structure of module 37. Triangle represents the miRNAs and circle represents the genes
Fig. 3Known interaction network for module 37. Triangle represents the miRNAs and circle represents the genes
Module enrichment performance of Mirsynergy and our method
| Method |
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|
| Mirsynergy | 18 | 88.4 | 21.9 | 1 | 1 | 4 | 1 |
| Our method | 46 | 42.6 | 10.3 | 14 | 8 | 15 | 7 |
‘ N module’ denotes the total number of modules identified. ‘’ and ‘’ denote the mean number of genes and miRNAs in the modules. ‘ N en-module’ denotes the number of enriched modules by clusters. ‘ N en-cluster’ denotes the number of enriched clusters by modules. ‘ N GO’, ‘ N KEGG’ denote the number of modules enriched by GO-BP and KEGG pathway